RSS Feed Print Category View
J&J, Medivir gain FDA OK for new hep C therapy simeprevir
ThomasKim
Posted: Monday, November 25, 2013 1:07 PM
Joined: 2/20/2013
Posts: 39


"Johnson & Johnson and its partner Medivir won a green light from the FDA late on Friday to begin marketing their hepatitis C drug simeprevir, which will now be sold as Olysio. The protease inhibitor is in the same class of drugs as Incivek and Victrelis, the two dominant therapies which will soon be pushed aside by a new wave of all-oral cocktails that will eliminate the need for interferon."

To read more, please visit: http://www.fiercebiotech.com/story/jj-medivir-gain-fda-ok-new-hep-c-therapy-simeprevir/2013-11-25?utm_medium=nl&utm_source=internal